All Interventions

    Omega-3 Fatty Acids

    Supplements
    Essential Fatty Acids

    Essential polyunsaturated fats (EPA/DHA) supporting cardiovascular, brain, and inflammatory health.

    Evidence Summary

    9
    / 10Score
    Strong
    Strong RCT Evidence

    Extensive RCT data for cardiovascular outcomes (REDUCE-IT). Well-established anti-inflammatory effects. Critical for brain health. UPDATE (August 2026): A systematic review of nutritional interventions and cellular senescence in humans (Ageing Research Reviews 2026; 27 trials, 3,811 participants) found that among dietary supplements, n-3 polyunsaturated fatty acids were the only class showing plausible modulation of selected inflammatory and SASP-related circulating markers - though the authors describe supplement evidence overall as limited and heterogeneous, and note that SASP-panel cytokines are not specific to senescent cells. This is consistent with, and adds mechanistic texture to, the established anti-inflammatory profile of omega-3s. It is not evidence that omega-3 supplementation reduces senescent-cell burden. UPDATE (October 2026): The DO-HEALTH Bio-Age analysis (Bischoff-Ferrari et al., Nature Aging 2025; n=777 adults aged 70+, 3 years) found that 1 g/day of omega-3 (330 mg EPA + 660 mg DHA) was associated with a small but consistent slowing of three next-generation DNA-methylation aging clocks versus placebo: GrimAge2 (-0.32 SD, 95% CI -0.06 to -0.59), DunedinPACE (-0.17 SD, 95% CI -0.04 to -0.31; ~1% slower pace of aging) and PhenoAge (-0.16 SD, 95% CI -0.02 to -0.30) - roughly 3-4 months less biological aging over 3 years. Adding vitamin D and strength training gave additive benefit on PhenoAge only; older clocks (Horvath, Hannum) and vitamin D or exercise alone showed no clear effect. Important context: the parent DO-HEALTH randomized trial (JAMA 2020, n=2,157) found that none of the three interventions significantly improved its primary clinical endpoints - blood pressure, non-vertebral fractures, physical function, cognition or infections - in generally healthy older adults. The epigenetic-clock result is a small, post hoc, surrogate-marker finding that is hypothesis-generating, not proof that omega-3 extends healthy lifespan. Omega-3's best-established benefits remain cardiovascular risk reduction and triglyceride lowering.

    Evidence Scale

    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    AnecdotalStrong RCT

    Mechanism of Action

    Incorporated into cell membranes, modulating fluidity. Precursors to anti-inflammatory resolvins and protectins. Support cardiovascular, neurological, and immune function.

    Who Is This For?

    Cardiovascular risk, inflammation, cognitive support, mood disorders. Omega-3 index testing available.

    Protocol & Dosing

    Dose

    2-4g combined EPA/DHA daily. Higher EPA for inflammation, balanced for general health.

    Frequency

    Daily with meals

    Duration

    Ongoing

    Protocol Summary

    Triglyceride or ethyl ester form. Take with food. EPA:DHA ratio varies by goal.

    Latest Evidence

    2025: DO-HEALTH links 1 g/day omega-3 to slower epigenetic aging

    In the DO-HEALTH Bio-Age analysis (Bischoff-Ferrari et al., Nature Aging 2025), 777 adults aged 70+ taking 1 g/day of omega-3 (330 mg EPA + 660 mg DHA) for three years showed a small but consistent slowing of three next-generation DNA-methylation aging clocks versus placebo — GrimAge2 (−0.32 SD), DunedinPACE (−0.17 SD, about 1% slower pace of aging) and PhenoAge (−0.16 SD), roughly equivalent to 3–4 months less biological aging over three years. Adding vitamin D and strength training produced additive benefit on PhenoAge. Older clocks (Horvath, Hannum) and vitamin D or exercise alone showed no clear effect.

    Important context: the parent DO-HEALTH randomized trial (JAMA 2020, n=2,157) found that none of the three interventions significantly improved its primary clinical endpoints — blood pressure, non-vertebral fractures, physical function, cognition or infections — in generally healthy older adults. The epigenetic-clock result is a small, post hoc, surrogate-marker finding that is hypothesis-generating, not proof that omega-3 extends healthy lifespan. Omega-3's best-established benefits remain cardiovascular risk reduction and triglyceride lowering; high doses can raise bleeding risk and a modest atrial-fibrillation signal has been reported. Individualize and target an omega-3 index >8% by testing. Educational information, not medical advice.

    DO-HEALTH Bio-Age · n=777 · 1 g/day omega-3 · 3-yr RCT

    Omega-3 slowed three DNA-methylation aging clocks

    Source: Bischoff-Ferrari et al., Nature Aging 2025 — DO-HEALTH Bio-Age analysis (n=777; 1 g/day omega-3 [330 mg EPA + 660 mg DHA]; 3 years). Standardized reductions vs. placebo: GrimAge2 −0.32 (95% CI −0.06 to −0.59), DunedinPACE −0.17 (−0.04 to −0.31), PhenoAge −0.16 (−0.02 to −0.30) — roughly 3–4 months less biological aging over 3 years. This is a small, post hoc, surrogate-marker effect; the parent DO-HEALTH trial (JAMA 2020) found no significant benefit on primary clinical endpoints. Educational information, not medical advice.

    Key references: Omega-3, vitamin D & exercise on DNA-methylation clocks — DO-HEALTH, Nature Aging (2025) · DO-HEALTH randomized trial: clinical outcomes in adults ≥70 — JAMA (2020) · Omega-3 fatty acids & cardiovascular outcomes: systematic review & meta-analysis — EClinicalMedicine (2021)

    Interactions & Precautions

    Contraindications

    • Fish allergy (fish-derived)
    • Anticoagulation (high doses)

    Potential Risks

    • •Oxidation if poor quality
    • •Bleeding risk at high doses

    Potential Side Effects

    Fishy burps
    GI upset
    Bleeding risk at very high doses

    Practitioner Notes

    Clinical annotations from Dr. Goel

    Triglyceride form superior absorption. Check for third-party testing. Target omega-3 index >8%. EPA dominant for cardiovascular/inflammatory goals. Updated August 2026: Omega-3s were the only supplement class in the 2026 human senescence systematic review to show plausible movement on SASP-related circulating markers. Worth noting to patients interested in senescence, with the caveat the authors themselves apply - these markers are not senescent-cell-specific, so this supports the anti-inflammatory case rather than a senolytic one. Primary indication remains cardiovascular and cognitive. Updated October 2026: The 2025 DO-HEALTH Bio-Age analysis adds a plausible aging-biology signal (slowed GrimAge2/DunedinPACE/PhenoAge on 1 g/day) to omega-3's established anti-inflammatory profile, but the parent trial was null on hard clinical endpoints - frame to patients as supportive, surrogate-marker evidence rather than a longevity guarantee. Primary, best-evidenced indications remain cardiovascular risk reduction (notably high-dose EPA) and hypertriglyceridemia; mind bleeding risk and the modest atrial-fibrillation signal at high doses. Continue to target an omega-3 index >8% and titrate to labs.
    SG

    Dr. Sanjeev Goel

    Chief Medical Officer, Peak Human

    Cost & Access

    Cost Range

    $

    Accessibility

    OTC supplement

    Availability varies by location

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation